Short interfering RNAs targeted to T-LAK cell-originated...

Details Short interfering RNAs targeted to T-LAK cell-originated... Short interfering RNAs targeted to T-LAK cell-originated...

2009-04-01

2011-10-25

Vivlemore, Tracy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C514S04400A

Reexamination Certificate

active

08044193

ABSTRACT:
Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells. In another embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS and IDC cells. The present invention further provides means for predicting and preventing breast cancer metastasis using BRC-associated genes having unique altered expression patterns in breast cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and method for vaccinating a subject against breast cancer.

REFERENCES:
patent: 6365358 (2002-04-01), Hillman et al.
patent: 2003/0104418 (2003-06-01), Zhang et al.
patent: 2003/0157544 (2003-08-01), Gish et al.
patent: 2004/0005563 (2004-01-01), Mack et al.
patent: 2005/0064402 (2005-03-01), Goldsworthy et al.
patent: WO 02/04514 (2002-01-01), None
patent: WO 02/29104 (2002-04-01), None
patent: WO 2004/031410 (2004-04-01), None
patent: WO 2006/085684 (2006-08-01), None
patent: WO 2008/018642 (2008-02-01), None
Pages 1-35 and 182 of WO 2004094636 A1 (38 pages total).
U.S. Appl. No. 12/377,024, which is a U.S. Nat'l Phase of PCT/JP2007/065992, filed Aug. 10, 2007, 221 pgs.
U.S. Appl. No. 12/673,432, which is a U.S. Nat'l Phase of PCT/JP2008/064437, filed Aug. 12, 2008, 83 pgs.
U.S. Appl. No. 12/673,434, which is a US National Stage (371) of PCT/JP2008/060837, 102 pgs.
Abe, Y., et al., “Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell originated protein kinase, specifically expressed in the testis and activated lymphoid cells,”The Journal of Biological Chemistry, 275(28):21525-21531 (Jul. 14, 2000).
Adam, Paul J. et al.; “ArylamineN-acetyltransferase-1 is highly expressed in breast cancers and conveys enhanced growth and resistance to etoposide in vitro”;Molecular Cancer Research1:826-835 (Sep. 2003).
Database EBI Accession No. AAM56211; “Sequence 1 from patent US 6365358” Jun. 20, 2002.
Database; EBI Accession No. AX369194; “Sequence from patent WO0204514”; Feb. 15, 2002.
Dermer, 1994, Bio/technology, 12: 320.
Dressman, Marlene A. et al.; “Gene expression in profiling detects gene amplification and differentiates tumor types in breast cancer”;Cancer Research63:2194-2199 (May 1, 2003).
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc. 1983, New York, p. 4).
Gaudet, S., et al., “Characterization of PDZ-binding kinase, a mitotic kinase,”Proc. Natl. Acad. Sci. USA, 97(10): 5167-5172 (May 9, 2000).
Geylan, Y.S. et al.; “Arylamine N-acetyltransferase activities in human breast cancer tissues”;Neoplasma48(2):108-111 (2001).
Gura, “Cancer Models: Systems for Identifying New Drugs Are Often Faulty,” 1997, Science, 278: pp. 1041-1042.
Lipkowitz, Stan; “The role of ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer”;Breast Cancer Research5(1):8-15 (2003).
Matsumoto et al., Biochemical and Biophysical Research Communications, Dec. 2004, 32:997-1004.
Orlowski, Robert Z. and E. Claire Dees; “The role of ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer”;Breast Cancer Research5(1):1-7 (2003).
Perou, Charles M. et al.; “Molecular portraits of human breast tumors”;Nature406:747-752 (Aug. 17, 2000).
Sgroi, Dennis C. et al.; “In vivo gene expression profile analysis of human breast cancer progression”;Cancer Research59:5656-5661 (Nov. 15, 1999).
Zhao, S., et al., “PDZ-binding kinase participates in spermatogenesis,”Int. J. of Biochem.&Cell Biol., 33(6): 631-636 (Jun. 2001).
Keydar, I., et al., “Establishment of Characterization of a Cell Line of Human Breast Carcinoma Origin,”Eur. J. Cancer, vol. 15(5), pp. 659-670 (May 1979).
Park, J-H., et al., “PDZ-Binding Kinase/T-LAK Cell-Originated Protein Kinase, a Putative Cancer/Testis Antigen with an Oncogenic Activity in Breast Cancer,”Cancer Res., vol. 66(18), pp. 9186-8195 (Sep. 15, 2006).
Park, J-H., et al., “PBK/TOPK (PDZ-binding kinase/T-LAK cell-originated protein kinase) as a novel molecular target for breast cancer therapy,”Proceedings of the 66thAnnual Meeting of the Japanese Cancer Association, p. 78, Abstract No. EW17-4 (Aug, 25, 2007).
Watanabe, T., et al., “Identification and characterization of a novel geneCXADRL1whose expression is frequently up-regulated in differentiated-type of gastric cancer,”Proceedings of the 61stAnnual Meeting of the Japanese Cancer Association, p. 77, Abstract No. 2027 (Aug. 25, 2002).

Affiliated with

Also associated with

Rating

Short interfering RNAs targeted to T-LAK cell-originated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Short interfering RNAs targeted to T-LAK cell-originated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Short interfering RNAs targeted to T-LAK cell-originated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4276119